Do you have pancreatic ductal adenocarcinoma that has come back after receiving standard therapy? If so, you may be able to participate in this gene therapy research study to learn more about using you own modified immune cells as possible treatment.

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.

Have you been diagnosed with breast cancer? If so, you may be able to take part in a research study for the collection of tumor specimens and genomic DNA from patients with early or metastatic breast cancer.

In this study, we want to learn if patients with advanced melanoma can stop treatment after 12 months of therapy.

Do you Patients with have Advanced Nasopharyngeal Carcinoma that has Progressed After Platinum Treatment and Immunotherapy? If so, you may be able to participate in a research study to find out if progression-free survival of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).

Do you have multiple myeloma with MGRS-associated kidney disease? If so, you may be able to take part in a research study looking at the safety and effectiveness of a combination of medications for patients with multiple myeloma with MGRS-associated kidney disease.

The purpose of this study is to understand what factors encourage and discourage rural and racially and ethnically diverse populations to participate in cancer clinical research studies. The study is focused on people living in Bertie, Hertford, Robseon and Scotland Co, NC and neighboring counties. We also want to hear what healthcare providers in these NC areas think about cancer clinical research barriers and facilitators.

Have you been diagnosed with Squamous cell carcinoma. Are you looking for options to treat your cancer ? If so, you may be able to take part in a research study looking at the safety of giving a new drug called iC9-CAR.CSPG4 and Rimiducid to patients with squamous cell carcinoma

We are doing this study to test a behavioral lifestyle program designed specifically for adolescent and young adult cancer survivors. Study participants will use a smartphone app and Fitbit activity tracker to help them develop healthier habits.